FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately

In wake of rimonabant, formal evaluation of depression will probably be needed for centrally acting drugs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet